$BCDA
BioCardia, Inc.

2021 Q4 Form 10-Q Financial Statement

#000143774921026143 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $79.00K $821.0K $34.00K
YoY Change 58.0% 2314.71% -82.47%
Cost Of Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Gross Profit $79.00K $821.0K $34.00K
YoY Change 58.0% 2314.71% -80.0%
Gross Profit Margin 100.0% 100.0% 100.0%
Selling, General & Admin $1.425M $1.289M $1.408M
YoY Change 16.8% -8.45% 1.29%
% of Gross Profit 1803.8% 157.0% 4141.18%
Research & Development $2.115M $2.240M $2.474M
YoY Change -9.23% -9.46% 23.27%
% of Gross Profit 2677.22% 272.84% 7276.47%
Depreciation & Amortization $15.00K $15.00K $15.00K
YoY Change -25.0% 0.0% -48.28%
% of Gross Profit 18.99% 1.83% 44.12%
Operating Expenses $3.540M $3.529M $3.882M
YoY Change -0.28% -9.09% 14.28%
Operating Profit -$3.461M -$2.708M -$3.848M
YoY Change -1.11% -29.63% 19.24%
Interest Expense $1.000K $2.000K $1.000K
YoY Change 100.0% -99.11%
% of Operating Profit
Other Income/Expense, Net -$1.000K $2.000K $0.00
YoY Change -100.0%
Pretax Income -$3.461M -$2.706M -$3.850M
YoY Change 15.75% -29.71% 1.58%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.461M -$2.706M -$3.848M
YoY Change 15.75% -29.68% 1.48%
Net Earnings / Revenue -4381.01% -329.6% -11317.65%
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$202.8K -$158.6K -$305.1K
COMMON SHARES
Basic Shares Outstanding 16.87M 16.87M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.87M $15.89M $7.390M
YoY Change -39.88% 114.99% -17.06%
Cash & Equivalents $12.87M $15.90M $7.392M
Short-Term Investments
Other Short-Term Assets $462.0K $358.0K $130.0K
YoY Change 15.5% 175.38% -27.78%
Inventory
Prepaid Expenses
Receivables $147.0K $198.0K $304.0K
Other Receivables $0.00 $562.0K $770.0K
Total Short-Term Assets $13.48M $17.01M $8.590M
YoY Change -40.5% 97.97% -7.0%
LONG-TERM ASSETS
Property, Plant & Equipment $182.0K $175.0K $161.0K
YoY Change 25.52% 8.7% -23.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $172.0K $0.00 $54.00K
YoY Change 218.52% -100.0% 0.0%
Total Long-Term Assets $2.237M $324.0K $912.0K
YoY Change 192.04% -64.47% -36.84%
TOTAL ASSETS
Total Short-Term Assets $13.48M $17.01M $8.590M
Total Long-Term Assets $2.237M $324.0K $912.0K
Total Assets $15.72M $17.33M $9.502M
YoY Change -32.9% 82.38% -11.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $507.0K $846.0K $1.208M
YoY Change -32.04% -29.97% 8.63%
Accrued Expenses $240.0K $79.00K $105.0K
YoY Change 175.86% -24.76% 2.94%
Deferred Revenue $847.0K $886.0K $90.00K
YoY Change 24.01% 884.44% -64.29%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $280.0K
YoY Change
Total Short-Term Liabilities $3.712M $3.918M $4.320M
YoY Change -12.62% -9.31% 6.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $230.0K
YoY Change -100.0%
Other Long-Term Liabilities $1.631M $840.0K
YoY Change -41.67%
Total Long-Term Liabilities $1.631M $0.00 $1.070M
YoY Change -100.0% -25.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.712M $3.918M $4.320M
Total Long-Term Liabilities $1.631M $0.00 $1.070M
Total Liabilities $5.343M $3.918M $5.389M
YoY Change 25.78% -27.3% -1.79%
SHAREHOLDERS EQUITY
Retained Earnings -$128.7M -$125.2M -$113.1M
YoY Change 10.87% 10.71% 15.9%
Common Stock $17.00K $17.00K $12.00K
YoY Change 6.25% 41.67% -73.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.38M $13.41M $4.113M
YoY Change
Total Liabilities & Shareholders Equity $15.72M $17.33M $9.502M
YoY Change -32.9% 82.38% -11.04%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$3.461M -$2.706M -$3.848M
YoY Change 15.75% -29.68% 1.48%
Depreciation, Depletion And Amortization $15.00K $15.00K $15.00K
YoY Change -25.0% 0.0% -48.28%
Cash From Operating Activities -$2.975M -$2.643M -$3.600M
YoY Change -13.01% -26.58% 144.9%
INVESTING ACTIVITIES
Capital Expenditures -$41.00K -$20.00K -$20.00K
YoY Change 0.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$41.00K -$20.00K -$20.00K
YoY Change 0.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 8.000K -70.00K
YoY Change -100.0% -111.43% -100.71%
NET CHANGE
Cash From Operating Activities -2.975M -2.643M -3.600M
Cash From Investing Activities -41.00K -20.00K -20.00K
Cash From Financing Activities 0.000 8.000K -70.00K
Net Change In Cash -3.016M -2.655M -3.690M
YoY Change -121.53% -28.05% -143.93%
FREE CASH FLOW
Cash From Operating Activities -$2.975M -$2.643M -$3.600M
Capital Expenditures -$41.00K -$20.00K -$20.00K
Free Cash Flow -$2.934M -$2.623M -$3.580M
YoY Change -14.21% -26.73% 146.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16871265
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
15000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
16000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16871265
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16871265
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16297381
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16297381
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1160000 USD
CY2020Q1 bcda Sharebased Compensation Arrangement By Sharebased Payment Award Remaining Weighted Average Award Vesting Period
SharebasedCompensationArrangementBySharebasedPaymentAwardRemainingWeightedAverageAwardVestingPeriod
P3Y
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15888000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21407000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
198000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
232000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
358000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
401000 USD
CY2021Q3 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
562000 USD
CY2020Q4 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
618000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
17006000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
22658000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
175000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
149000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
567000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23424000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
821000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
34000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
936000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
99000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2240000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2474000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6443000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7484000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000 USD
CY2021Q3 us-gaap Assets
Assets
17330000 USD
CY2020Q4 us-gaap Assets
Assets
23424000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
846000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
746000 USD
CY2021Q3 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2025000 USD
CY2020Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2205000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
886000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
683000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
161000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
614000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
3918000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
4248000 USD
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
17000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
16000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
138631000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135234000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125236000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116074000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
13412000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
19176000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17330000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1289000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1408000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3662000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4642000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
3529000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
3882000 USD
us-gaap Costs And Expenses
CostsAndExpenses
10105000 USD
us-gaap Costs And Expenses
CostsAndExpenses
12130000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2708000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3848000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9169000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12031000 USD
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
8000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
19000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
16000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2706000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3848000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9162000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12015000 USD
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.33
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17066068
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12618285
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16867652
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9059433
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
19176000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1934000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
416000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2969000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
18562000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
384000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
214000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3487000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
15673000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
437000 USD
CY2021Q3 bcda Adjustments To Additional Paid In Capital Stock Issued Refund Of Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedRefundOfIssuanceCosts
8000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2706000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
13412000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2370000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
941000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4594000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1283000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10340000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
148000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
655000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3573000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
7291000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
67000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
737000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3848000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
4113000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9162000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12015000 USD
us-gaap Inventory Write Down
InventoryWriteDown
0 USD
us-gaap Inventory Write Down
InventoryWriteDown
3000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52000 USD
bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
418000 USD
bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
368000 USD
bcda Noncash Compensation Expense
NoncashCompensationExpense
0 USD
bcda Noncash Compensation Expense
NoncashCompensationExpense
115000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1237000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2333000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-34000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
157000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-97000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-510000 USD
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
-56000 USD
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
762000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
100000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
294000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
34000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
715000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
203000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8000 USD
bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
-453000 USD
bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
64000 USD
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
0 USD
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-453000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7391000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8940000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
75000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-75000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2001000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11500000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
59000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1227000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
506000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1947000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10779000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5519000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1807000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21407000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5585000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15888000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7392000 USD
bcda Proceeds From Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
ProceedsFromIssuanceOfRestrictedStockUnitsInLieuOfCashBonus
393000 USD
bcda Proceeds From Issuance Of Restricted Stock Units In Lieu Of Cash Bonus
ProceedsFromIssuanceOfRestrictedStockUnitsInLieuOfCashBonus
391000 USD
bcda Issuance Of Restricted Stock Units In Lieu Of Cash Compensation
IssuanceOfRestrictedStockUnitsInLieuOfCashCompensation
0 USD
bcda Issuance Of Restricted Stock Units In Lieu Of Cash Compensation
IssuanceOfRestrictedStockUnitsInLieuOfCashCompensation
613000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
148000 USD
bcda Noncash Interest Expense Accretion To Loan Payable
NoncashInterestExpenseAccretionToLoanPayable
0 USD
bcda Noncash Interest Expense Accretion To Loan Payable
NoncashInterestExpenseAccretionToLoanPayable
2000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125200000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15900000 USD
us-gaap Use Of Estimates
UseOfEstimates
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;"><tbody><tr><td style="vertical-align: top; width: 5%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>(c)</i></b></p> </td><td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>  Use of Estimates</i></b></p> </td></tr> <tr><td style="vertical-align: top; width: 5%;"> </td><td style="vertical-align: top; width: 3%;"> </td><td style="vertical-align: top; width: 92%;"> </td></tr> <tr><td style="vertical-align: top; width: 5%;"> </td><td style="vertical-align: top; width: 3%;"> </td><td style="vertical-align: top; width: 92%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, right-of-use assets and related liabilities, incremental borrowing rate, allowances for doubtful accounts and sales returns, derivative instruments, clinical accruals, inventory valuation, and assumptions used for revenue recognition.</p> </td></tr> </tbody></table> <p style="margin: 0pt;"> </p>
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1245000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1170000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1070000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1025000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
175000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000 USD
CY2021Q3 us-gaap Depreciation
Depreciation
15000 USD
us-gaap Depreciation
Depreciation
45000 USD
CY2020Q3 us-gaap Depreciation
Depreciation
15000 USD
us-gaap Depreciation
Depreciation
52000 USD
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
451000 USD
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
451000 USD
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
162000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
486000 USD
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
158000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
473000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1205 pure
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
162000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
161000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
87000 USD
CY2021Q3 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
900000 USD
CY2020Q4 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
961000 USD
CY2021Q3 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
350000 USD
CY2020Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
452000 USD
CY2021Q3 bcda Grant Liability Current
GrantLiabilityCurrent
600000 USD
CY2020Q4 bcda Grant Liability Current
GrantLiabilityCurrent
615000 USD
CY2021Q3 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
96000 USD
CY2020Q4 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
90000 USD
CY2021Q3 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2025000 USD
CY2020Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2205000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
125
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.32
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1684066
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
772435
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.56
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1580
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
200970
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2424724
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
bcda Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
bcda Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
0
bcda Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
-0
bcda Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
0
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2424724
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
437000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
737000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1237000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2333000 USD
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.32
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
515036
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
569000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
412000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
157000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1114306
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.89
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
177100 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
118900 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
691317
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
34900 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4114258
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3522820
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD

Files In Submission

Name View Source Status
0001437749-21-026143-index-headers.html Edgar Link pending
0001437749-21-026143-index.html Edgar Link pending
0001437749-21-026143.txt Edgar Link pending
0001437749-21-026143-xbrl.zip Edgar Link pending
bcda-20210930.xsd Edgar Link pending
bcda-20210930_cal.xml Edgar Link unprocessable
bcda-20210930_def.xml Edgar Link unprocessable
bcda-20210930_lab.xml Edgar Link unprocessable
bcda-20210930_pre.xml Edgar Link unprocessable
bcda20210930_10q.htm Edgar Link pending
bcda20210930_10q_htm.xml Edgar Link completed
ex_303311.htm Edgar Link pending
ex_303312.htm Edgar Link pending
ex_303313.htm Edgar Link pending
ex_303314.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending